Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview
- 827 Downloads
Complete resection constitutes the only curative approach in pancreatic cancer but is possible only in a minority of patients due to advanced stages upon diagnosis. Consequently, early detection is crucial for curative treatment. Clinical routine still lacks efficient, non-invasive screening assays, and 80–90% of pancreatic carcinomas are detected at unresectable stages. A wide range of serum proteins have been in the focus of intensive search for biomarkers specific for pancreatic cancer. This article will give an overview on serum biomarkers with screening potential for pancreatic malignancy.
Design and methods
PUBMED database was searched for articles, and 43 manuscripts were selected that provided data regarding biomarkers used, type of assay, study population, sample cohort quality and diagnostic performance.
Superior values for diagnostic performance were shown for MIC-1, PAM4, OPN, HSP27, TPS, TSGF, and CAM17.1 as individual markers. Panels of biomarkers comprised CA 19-9, MCSF, CEA, SAA, Haptoglobin, TSGF, CA 242, and HSP27. Individually or in concerted form, sensitivity and specificity ranged from 77 to 100% and 84–100%, respectively.
While the above named markers show high screening potential for pancreatic cancer, standardized validation studies using multiplex assays are required to pave the way for clinical routine application.
KeywordsEarly detection Pancreatic cancer screening Serum biomarker Serum diagnostics Tumor marker
We declare that we have no conflict of interest. Grants from the Ad Infinitum Foundation, the Werner and Clara Kreitz Foundation and the H.W. & J. Hector Foundation are gratefully acknowledged. This review was performed in collaboration with the “North German Tumorbank of Colorectal Cancer” (DKH #108446) and the biobank “ColonBiomics” being integral part of the Surgical Center for Translational Oncology-Lübeck (SCTO-L).
Conflict of interest
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1–6CrossRefPubMedGoogle Scholar
- Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K (2006) Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 141:968–973 ;(discussion 974)Google Scholar
- Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C et al (2009) Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 15:3812–3819CrossRefPubMedGoogle Scholar
- Galasso D, Carnuccio A, Larghi A (2010) Pancreatic cancer: diagnosis and endoscopic staging. Eur Rev Med Pharmacol Sci 14:375–385Google Scholar
- Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban R, Goldenberg DM (2010) Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers PrevGoogle Scholar
- Joergensen MT, Brunner N, De Muckadell OB (2010) Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res 30:587–592Google Scholar
- McSweeney SE, O’Donoghue PM, Jhaveri K (2010) Current and emerging techniques in gastrointestinal imaging. J Postgrad Med 56:109–116Google Scholar
- Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38:613–618CrossRefPubMedGoogle Scholar
- Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E (1994) A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 69:562–565CrossRefPubMedGoogle Scholar
- Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, Onofrj M, Gambi D, Sacchetta P, Di Ilio C et al (2010) Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J Proteomics 73:579–592Google Scholar